-
Abstract Number: PB0882
Rab GTPase Protein localization, regulation and function in platelets
-
Abstract Number: OC 19.1
Rabeprazole is an Agonist of HIF-1 and Promotes Vascular Repair and Resolution of Inflammatory Lung Injury
-
Abstract Number: PB0400
Rac1 inhibition causes impaired GPVI signalling in human platelets through GPVI shedding and loss of PLCγ2 phosphorylation
-
Abstract Number: PB0194
Race, ethnicity and F8 mutation type influence inhibitor risk: Analysis of the “My Life Our Future” Hemophilia Database
-
Abstract Number: PB1087
Rapid Detection of Exposure to Direct Oral Anticoagulants (DOACs): A Qualitative Urinary Dipstick Point-of-Care Assay
-
Abstract Number: PB0326
Rapid immunoassay for platelet factor-4 in the diagnosis of vaccine-induced immune thrombotic thrombocytopenia after vaccination with ChAdOx1 nCoV-19
-
Abstract Number: PB0992
Rare cases of acquired bleeding disorders in adolescents and young adults
-
Abstract Number: PB0277
Rate of recurrent venous thromboembolism in infants with unprovoked venous thromboembolism
-
Abstract Number: PB0493
Reach, Adoption, and Maintenance of a Population Health Dashboard for Safe DOAC Prescribing: Insights from the United States Veterans Health Affairs
-
Abstract Number: PO0071
Real World Data : Safety and Mortality Monitoring the patients on Rivaroxaban in our center
-
Abstract Number: PB0276
Real World Data of Pediatric Thromboembolic Disease by the International Pediatric Thrombosis Network
-
Abstract Number: PB1145
Real World Experience of perioperative haemostasis with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in people with Haemophilia A (PWHA)
-
Abstract Number: PB0649
Real world experience using rIX-FP prophylaxis in patients with haemophilia B: experience from a Spanish centre.
-
Abstract Number: OC 15.3
Real World use of Apixaban for the Prevention and Treatment of Thrombosis in Children with Cardiac and Complex Disease
-
Abstract Number: VPB0503
Real- world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia
-
Abstract Number: VPB0573
Real-life behavior of direct oral anticoagulants in the elderly population with atrial fibrillation
-
Abstract Number: VPB0574
Real-life behavior of direct oral anticoagulants in the population with chronic kidney disease and atrial fibrillation
-
Abstract Number: PB0403
Real-time assessment of inter-platelet communication and coordination of calcium signals by connexin gap junctions
-
Abstract Number: PB0687
Real-world efficacy of extended half-life Factor VIII in patients with haemophilia A on prophylaxis
-
Abstract Number: PB1130
Real-world evidence on emicizumab in 119 Hemophilia A patients with inhibitors from the French FranceCoag cohort
-
Abstract Number: OC 70.4
Real-world management of delivery in a large cohort of haemophilia carriers: focus on maternal and neonatal outcomes.
-
Abstract Number: PB1031
Real-world treatment of severe congenital protein C deficiency with protein C concentrate including prophylaxis: A physician survey in Europe and the US
-
Abstract Number: PB1163
Real-World Unmet Needs of Patients with Haemophilia A/B with or without Inhibitors: Historical Haemophilia Characteristics from Patients Entering a Non-Interventional Study
-
Abstract Number: PB1148
Real-world usage of extended half-life FIX in a Portuguese Haemophilia Centre – prophylaxis must be for moderate and severe hemophilia B patients
-
Abstract Number: PB0453
Real-world Use of Andexanet Alfa for Anti-Xa Inhibitor Reversal: A Case Series
-
Abstract Number: PB0686
Real-world use of recombinant factor IX albumin fusion protein (rIX-FP) in patients with hemophilia B: A prospective, multicenter, non-interventional post-marketing surveillance study in France
-
Abstract Number: OC 27.4
Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A – results from A-SURE, a 24-month prospective, non-interventional study
-
Abstract Number: PB0057
Recovery after COVID-19 and persisting Endothelial Cell Activation and Hypercoagulability- The Prospective Observational ROADMAP-Post COVID-19 Study
-
Abstract Number: OC 06.2
Recurrence risk of a first systemic lupus erythematosus-associated venous thromboembolism: a retrospective cohort study
-
Abstract Number: PO0032
Recurrent arterial thrombosis in haemophilia A
-
Abstract Number: OC 23.3
Recurrent venous-thromboembolism: association with thrombin generation and D-Dimer
-
Abstract Number: PB1363
Red-light exposure reduces venous thrombosis in mice
-
Abstract Number: PB1044
Reference Interval of Antithrombin, Protein C, and Protein S Activities in Healthy Adults in Iran, The effect of Age, Sex, Oral Contraceptive Intake, and Menopause
-
Abstract Number: PO0018
Reference Range Determination for the Novel T-TAS 01 AR Assay
-
Abstract Number: PB0300
Refractory Acquired Thrombocytopenic Thrombotic Purpura with Genetic Polymorphism Complement System
-
Abstract Number: OC 67.3
Regulatory Function of the Anticoagulant Protein S in Patients with Chuvash Polycythemia
-
Abstract Number: PB0505
Relation among Brain Derived Neurotrophic Factor, depression, and extracellular vesicles-derived miRNA – results from an Italian cohort
-
Abstract Number: VPB0314
Relationship between recurrence of congenital and immune-mediated thrombotic thrombocytopenic purpura and mRNA-based COVID-19 vaccination: A questionnaire survey in a Japanese cohort
-
Abstract Number: LB 01.3
Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1
-
Abstract Number: VPB0517
Relationship of decreased levels of omentin-1 with prothrombotic state in coronary artery disease
-
Abstract Number: VPB0287
Relationship of Hemostasiological Properties of Blood in Children of Different Age Groups
-
Abstract Number: PB1021
Renal failure-induced coagulation factor increase is similarly worsened by Haemodialysis and Haemodiafiltration
-
Abstract Number: VPB0419
Renal function at enrollment but not change over time is associated with arterial thrombotic events in patients positive for lupus anticoagulant
-
Abstract Number: VPB0471
RENAL FUNCTION IMPACT IN CLINICAL AND BIOLOGIAL RESULTS FROM PATIENTS TREATED WITH DOACs IN REAL WORLD
-
Abstract Number: PO0069
Rendu-Osler disease and recurrent thromboembolic venous disease
-
Abstract Number: PO0028
Report of clinical case: Acquired hemophilia with a high-titer inhibitor and hemorrhagic diathesis.
-
Abstract Number: PB0586
Repurposing of Montelukast in COVID-19 patients in order to modulate platelet activation
-
Abstract Number: OC 21.1
Rescue of an FVIII splicing variant with engineered U1snRNAs
-
Abstract Number: OC 12.3
Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR/Cas9 mRNA LNPs
-
Abstract Number: PB0973
Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: a systematic review and meta-analysis of individual participant data
-
Abstract Number: PB0818
Response rate of different DDAVP dosing in Haemophilia A and von Willebrand disease
-
Abstract Number: PB0797
Restoration of VWF in Von Willebrand Disease type 3 canine ECFCs through CRISPR-Cas9 mediated gene editing
-
Abstract Number: PB0012
Restrictive versus Liberal Transfusion Strategy for Anemic Patients with Acute Myocardial Infarction: A Systematic Review and Meta-Analysis
-
Abstract Number: PB0213
Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients with Hemophilia B
-
Abstract Number: PB1098
Results in Patients with Heparin Induced Thrombocytopenia or Vaccine Induced Thrombocytopenia with Thrombosis Confirm the Unsuitability of Using APTT Ratio to Monitor Argatroban Therapy
-
Abstract Number: PB0307
Results of a Single-centre Targeted Screening Approach to Identify Potential Occult Cases of Pregnancy-associated Thrombotic Thrombocytopenic Purpura (TTP).
-
Abstract Number: PB1092
Results of samples spiked with chimeric monoclonal anti-PF4 antibody 1C12 in ECAT external quality assessment surveys for heparin-induced thrombocytopenia diagnosis.
-
Abstract Number: PB0182
Results of the implementation of home management in times of the covid-19 pandemic in patients with hemophilia A in Colombia
-
Abstract Number: PB1088
Results of the thrombin time test obtained with two different commercial reagents in real life patients treated with dabigatran
-
Abstract Number: PB0667
Results of thromboelastography and thrombin generation assays for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes
-
Abstract Number: PB0172
Results of thromboelastometry and thrombin generation assays for emicizumab prophylaxis monitoring
-
Abstract Number: PB0459
Retrieval rate and complications of inferior vena cava filters placed during acute venous thromboembolism.
-
Abstract Number: PB1161
Retrospective analysis of treatment individualization on hemophilia B patients from two Spanish centers who switched from SHL-FIX products to rIX-FP
-
Abstract Number: VPB0280
Retrospective Case Series Study of patients with May-Thurner Syndrome in a single Tertiary Pediatric Center
-
Abstract Number: PB0811
Retrospective Cohort Study of GPIbM and D1472H in Patients Referred for Von Willebrand Disease Testing
-
Abstract Number: OC 55.1
Retrotransposon insertions: a challenging detection and characterization solved by long-read nanopore sequencing. Relevance in antithrombin deficiency
-
Abstract Number: PB1012
Review of a Peri-operative mobile application to conform anticoagulation management and review of safety and clinician satisfaction.
-
Abstract Number: VPB0795
Reviewing atypical Hemolytic Uremic Syndrome in a portuguese terciary hospital
-
Abstract Number: VPB1422
Revision of the diagnostic methods used for the detection of pulmonary embolism in pregnant women at the Centre Hospitalier Universitaire de Sherbrooke
-
Abstract Number: PB1037
Rewarming from accidental hypothermia enhances whole blood coagulation in a mouse model
-
Abstract Number: PB0353
RhoB drives megakaryocyte transendothelial migration in RhoA-deficient mice
-
Abstract Number: OC 59.2
Ribosomal biogenesis inhibition facilitates megakaryocyte/platelet biased haematopoiesis
-
Abstract Number: PB0968
Right heart thrombus and pulmonary embolism: early diagnosis and therapeutic management
-
Abstract Number: OC 52.2
Risk and impact of anticoagulation-associated abnormal menstrual bleeding in women of reproductive age with venous thromboembolism – the TEAM-VTE study
-
Abstract Number: OC 61.1
Risk factors for bleeding after recent medical hospitalization: The Medical Inpatient Thrombosis and Hemostasis Study (MITH)
-
Abstract Number: PB0676
Risk factors for bleeding in people living with Hemophilia A and B treated with regular prophylaxis: a systematic review of the literature.
-
Abstract Number: VPB0998
Risk factors for intracranial hematomas during anticoagulant therapy
-
Abstract Number: PB0915
Risk Factors of Venous Thromboembolism among Elderly Patients with Acute Myeloid Leukemia by Race in the United States
-
Abstract Number: PB1352
Risk Factors of Venous Thromboembolism in Patients with Varicose Disease of the Lower Extremities
-
Abstract Number: PB0501
Risk of anticoagulant-related nephropathy early after initiating treatment
-
Abstract Number: PB1368
Risk of bleeding and venous thromboembolism in patients using therapeutic dosage of Direct Oral Anticoagulants undergoing total hip or total knee arthroplasty
-
Abstract Number: OC 14.3
Risk of long-term mortality in elderly patients with venous thrombosis
-
Abstract Number: PB0458
Rivaroxaban for management of Superficial Vein Thrombosis
-
Abstract Number: PB0270
Rivaroxaban for the treatment of thrombosis in pediatric patients with leukemia. Results of a pilot study
-
Abstract Number: PB1372
Rivaroxaban in patients with intestinal failure on parenteral nutrition (TINCRBEL study)
-
Abstract Number: OC 54.1
Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer
-
Abstract Number: PB1265
Role of a cellular antiprotease named Protease-Nexin-1 in the development of atherosclerosis
-
Abstract Number: VPB1140
Role of activated platelets in compensation of bleeding severity in Hemophilia A
-
Abstract Number: OC 09.5
Role of disturbed blood flow in the intrinsic thrombogenicity of human carotid stents
-
Abstract Number: OC 07.1
Role of GABARAP protein in the intracellular distribution of FVIII
-
Abstract Number: PB1252
Role of matrix Gla protein in vascular calcification: hard chemistry for soft vessels
-
Abstract Number: PB0623
Role of Transglutaminase 2 in Haemostasis and as a Novel Treatment Option for Acquired Autoimmune Factor XIII Deficiency
-
Abstract Number: PB0725
Role of von Willebrand factor Antigen as Non-invasive Biomarker for the Prediction of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis
-
Abstract Number: LB 02.5
Roles of FVIII in endothelial cell biology more than a coagulation factor
-
Abstract Number: PB0330
Romiplostim (Nplate) Use for Thrombocytopenia at a Large Academic Medical Center
-
Abstract Number: PB1241
Rotational thromboelastometry (ROTEM) in patients with bleeding of unknown cause: evidence for hemostatic imbalance
-
Abstract Number: PB0062
Rotational thromboelastometry in heparin monitoring in critical COVID-19 disease.
-
Abstract Number: PB1071
Routine Measurement of Direct Factor Xa Inhibiting Anticoagulants
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.